Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2015 Oct 29;76(6):1297–1307. doi: 10.1007/s00280-015-2879-4

Figure 3. Caspase-3 activation precedes changes in viability and DNA fragmentation in acute leukemia cells and cardiomyocytes.

Figure 3

A) Jurkat B) ML-1 and C) H9C2 cells were treated at 4, 8, 16 and 24 hours with DOX and DNR. Mean fold increase of fluorescence (DEVD-AMC) was measured by spectrofluorometry as an indication of caspase-3 activity (results were normalized to control). D) Jurkat and E) ML-1 cells were pretreated with pancaspase inhibitor Z-vad-fmk (20 µM) and then exposed to anthracyclines for 24 hours. Caspase-3 activity was quantified by measurement of mean fold increase of fluorescence (DEVD-AMC) by spectrofluorometry. Results were normalized to control and represent the mean ± SEM of 3 different experiments Mean ± SEM of 3 different experiments are represented. *p<0.05, **p<0.01, ns= not significant.